

Table.

		Lenvatinib + Pembrolizumab (n=31)
Efficacy		
Confirmed ORR, % (95% CI)		32 (17–51)
Disease control rate, ^a % (95% CI)		74 (55–88)
Duration of response, median (range) months		NR (1.5+ to 7.9+)
Progression-free survival, median (95% CI) months		4.4 (4.0–8.5)
Responders by prior therapy, n (%) ^b		
Platinum refractory/resistant (n=25)		6 (24)
Bevacizumab exposed (n=19)		4 (21)
Treatment-related AEs, n (%)		29 (94)
Grade 3–5 treatment-related AEs		21 (68)
Treatment-related AEs leading to death		1 (3) ^c
Treatment-related AEs resulting in treatment discontinuation		4 (13)
Treatment-related AEs occurring in ≥10 patients		
	Any Grade ^d	Grade 3
Hypertension	17 (55)	6 (19)
Fatigue	13 (42)	3 (10)
Hypothyroidism	13 (42)	0
Decreased appetite	12 (39)	0
Diarrhea	12 (39)	1 (3)
Proteinuria	10 (32)	2 (6)

^aDefined as best overall response of complete or partial response, or stable disease.

^bPercentages are based on the total number of patients in each prior therapy subgroup. ^cOne patient had a serious AE of hypovolemic shock that led to death. ^dAmong treatment-related AEs occurring in ≥10 patients, none were grade 4/5. AE, adverse event; NR, not reached; ORR, objective response rate.